Logo image of CFMS

Conformis Inc (CFMS) Stock Fundamental Analysis

NASDAQ:CFMS - Nasdaq - US20717E2000 - Common Stock - Currency: USD

2.26  0 (0%)

After market: 2.26 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to CFMS. CFMS was compared to 189 industry peers in the Health Care Equipment & Supplies industry. CFMS has a bad profitability rating. Also its financial health evaluation is rather negative. CFMS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CFMS had negative earnings in the past year.
CFMS had a negative operating cash flow in the past year.
In the past 5 years CFMS always reported negative net income.
CFMS had a negative operating cash flow in each of the past 5 years.
CFMS Yearly Net Income VS EBIT VS OCF VS FCFCFMS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M -50M

1.2 Ratios

The profitability ratios for CFMS are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CFMS Yearly ROA, ROE, ROICCFMS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -50 -100 -150 -200

1.3 Margins

Looking at the Gross Margin, with a value of 33.21%, CFMS is doing worse than 70.85% of the companies in the same industry.
In the last couple of years the Gross Margin of CFMS has remained more or less at the same level.
CFMS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.62%
GM growth 5Y0.29%
CFMS Yearly Profit, Operating, Gross MarginsCFMS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 50 -50

More info and screens

3

2. Health

2.1 Basic Checks

CFMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CFMS has been increased compared to 1 year ago.
The debt/assets ratio for CFMS is higher compared to a year ago.
CFMS Yearly Shares OutstandingCFMS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
CFMS Yearly Total Debt VS Total AssetsCFMS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -12.53, we must say that CFMS is in the distress zone and has some risk of bankruptcy.
CFMS has a worse Altman-Z score (-12.53) than 85.93% of its industry peers.
A Debt/Equity ratio of 0.64 indicates that CFMS is somewhat dependend on debt financing.
CFMS has a worse Debt to Equity ratio (0.64) than 70.85% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Altman-Z -12.53
ROIC/WACCN/A
WACC10.06%
CFMS Yearly LT Debt VS Equity VS FCFCFMS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

CFMS has a Current Ratio of 5.07. This indicates that CFMS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CFMS (5.07) is better than 64.32% of its industry peers.
A Quick Ratio of 3.30 indicates that CFMS has no problem at all paying its short term obligations.
With a Quick ratio value of 3.30, CFMS perfoms like the industry average, outperforming 58.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.07
Quick Ratio 3.3
CFMS Yearly Current Assets VS Current LiabilitesCFMS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M

More info and screens

3

3. Growth

3.1 Past

CFMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.00%, which is quite impressive.
The Revenue has decreased by -5.72% in the past year.
Measured over the past years, CFMS shows a decrease in Revenue. The Revenue has been decreasing by -4.50% on average per year.
EPS 1Y (TTM)34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.89%
Revenue 1Y (TTM)-5.72%
Revenue growth 3Y-7.12%
Revenue growth 5Y-4.5%
Sales Q2Q%-14.85%

3.2 Future

The Earnings Per Share is expected to grow by 15.18% on average over the next years. This is quite good.
The Revenue is expected to grow by 0.56% on average over the next years.
EPS Next Y24.27%
EPS Next 2Y15.18%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-8.57%
Revenue Next 2Y0.56%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CFMS Yearly Revenue VS EstimatesCFMS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CFMS Yearly EPS VS EstimatesCFMS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CFMS. In the last year negative earnings were reported.
Also next year CFMS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CFMS Price Earnings VS Forward Price EarningsCFMS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CFMS Per share dataCFMS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

A more expensive valuation may be justified as CFMS's earnings are expected to grow with 15.18% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.18%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CFMS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Conformis Inc

NASDAQ:CFMS (9/1/2023, 8:00:15 PM)

After market: 2.26 0 (0%)

2.26

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-02 2023-08-02/amc
Earnings (Next)10-31 2023-10-31/amc
Inst Owners0.01%
Inst Owner Change-99.93%
Ins Owners110.05%
Ins Owner Change0%
Market Cap17.80M
Analysts80
Price Target2.32 (2.65%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-14.47%
Min EPS beat(2)-35.81%
Max EPS beat(2)6.86%
EPS beat(4)2
Avg EPS beat(4)9.06%
Min EPS beat(4)-35.81%
Max EPS beat(4)72.14%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)1.6%
Min Revenue beat(2)0.13%
Max Revenue beat(2)3.06%
Revenue beat(4)3
Avg Revenue beat(4)6.67%
Min Revenue beat(4)-1.47%
Max Revenue beat(4)24.96%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-95.46%
PT rev (3m)-95.46%
EPS NQ rev (1m)8.04%
EPS NQ rev (3m)8.04%
EPS NY rev (1m)0%
EPS NY rev (3m)0.25%
Revenue NQ rev (1m)2.16%
Revenue NQ rev (3m)2.16%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.31
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-5.61
EYN/A
EPS(NY)-4.72
Fwd EYN/A
FCF(TTM)-5.92
FCFYN/A
OCF(TTM)-5.65
OCFYN/A
SpS7.24
BVpS4.07
TBVpS4.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.21%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.62%
GM growth 5Y0.29%
F-Score1
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.41%
Cap/Sales 3.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.07
Quick Ratio 3.3
Altman-Z -12.53
F-Score1
WACC10.06%
ROIC/WACCN/A
Cap/Depr(3y)58.59%
Cap/Depr(5y)68.68%
Cap/Sales(3y)3.37%
Cap/Sales(5y)3.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.89%
EPS Next Y24.27%
EPS Next 2Y15.18%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-5.72%
Revenue growth 3Y-7.12%
Revenue growth 5Y-4.5%
Sales Q2Q%-14.85%
Revenue Next Year-8.57%
Revenue Next 2Y0.56%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year46.42%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-299.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-342.58%
OCF growth 3YN/A
OCF growth 5YN/A